1. Home
  2. GAB vs IMCR Comparison

GAB vs IMCR Comparison

Compare GAB & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Equity Trust Inc. (The)

GAB

Gabelli Equity Trust Inc. (The)

HOLD

Current Price

$5.21

Market Cap

1.9B

Sector

Finance

ML Signal

HOLD

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

HOLD

Current Price

$32.29

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GAB
IMCR
Founded
1986
2008
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.5B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
GAB
IMCR
Price
$5.21
$32.29
Analyst Decision
Buy
Analyst Count
0
13
Target Price
N/A
★ $62.73
AVG Volume (30 Days)
★ 1.1M
503.3K
Earning Date
01-01-0001
11-05-2026
Dividend Yield
★ 10.91%
N/A
EPS Growth
N/A
★ 30.39
EPS
N/A
★ 0.23
Revenue
N/A
★ $249,428,000.00
Revenue This Year
N/A
$13.06
Revenue Next Year
N/A
$8.12
P/E Ratio
★ N/A
$139.20
Revenue Growth
N/A
★ 43.05
52 Week Low
$5.12
$27.50
52 Week High
$6.37
$40.71

Technical Indicators

Market Signals
Indicator
GAB
IMCR
Relative Strength Index (RSI) 43.08 57.89
Support Level $5.12 $32.03
Resistance Level $5.72 $33.62
Average True Range (ATR) 0.07 1.24
MACD 0.02 0.53
Stochastic Oscillator 52.26 76.67

Price Performance

Historical Comparison
GAB
IMCR

About GAB Gabelli Equity Trust Inc. (The)

Gabelli Equity Trust Inc is a non-diversified closed-end management investment company. Its primary investment objective is the long-term growth of capital with income as a secondary objective. The Fund invests at least its assets in equity securities under normal market conditions. Its equity portfolio includes common stock, preferred stock, convertible or exchangeable securities, and warrants and rights to purchase such securities selected by the Investment Adviser. The company invests in various sectors, of which Food & Beverage, Financial Services, Equipment and Supplies, Entertainment, Consumer Products, Health Care, Diversified Industrial, Business Services, Consumer Services and others.

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Share on Social Networks: